EPISODE · Mar 4, 2017 · 13 MIN
Cost and Survival Analysis before and after Implementation of Dana-Farber Clinical Pathways for Patients with Stage IV Non-Small Cell Lung Cancer
from JCO Oncology Practice Podcast · host Dr. Nathan Pennell
Dr. David Jackman of Dana-Farber Cancer Institute discusses how after introduction of a clinical pathway in metastatic NSCLC, cost of care decreased significantly with no compromise in survival.
Embed this episode
NOW PLAYING
Cost and Survival Analysis before and after Implementation of Dana-Farber Clinical Pathways for Patients with Stage IV Non-Small Cell Lung Cancer
0:00
13:38
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of JCO Oncology Practice Podcast?
This episode is 13 minutes long.
When was this JCO Oncology Practice Podcast episode published?
This episode was published on March 4, 2017.
Can I download this JCO Oncology Practice Podcast episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!